secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001104659-23-079684
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance reports ~$317M cash as of June 30; authorized shares increased to 500M
------------------------------------------------------------------------------

- Preliminary cash, equivalents, short-term investments, and restricted cash ~$317M as of June 30, 2023 (unaudited).
- Stockholders approved increase in authorized common stock from 300M to 500M at June 6 annual meeting; certificate filed June 9.
- The cash estimate is subject to change upon completion of quarter-end closing procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923079684/0001104659-23-079684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923079684/tm2320915d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-079684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer